We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Research activities continue to be a target of enforcement efforts by the FDA, which last week published two more warning letters issued to clinical investigators (CIs).